| Authors | O. M. Shaaban, A. M. Abbas, K. M. Zahran, M. M. Fathalla, M. A. Anan and S. A. Salman |
| Journal | Thrombosis/Clinical and applied Hemostasis |
| Year of publication | 2016 |
| Country | Egypt |
| Period | From January 1st, 2011 to December 2014. |
| Study Designer | Prospective randomized study |
| Randomization | A computer performed randomization and eligible patients were randomly assigned to one of two groups. |
| Inclusion criteria | Pregnant women between 20 and 35 years with regular marital life with the same partner, regular menstrual cycle before current pregnancy, cutaneous conception and history of habitual abortion defined as 3 or more consecutive miscarriages before 20 weeks of gestation. |
| Exclusion criteria | Women with polycystic ovary syndrome, any endocrine abnormalities such as diabetes mellitus, thyroid disorders, history of abnormal uterine cavity proven by hysterosonography or hysteroscopy before pregnancy. Women with positive inbreeding. Women who refused to participate. |
| Participant demographic data | Women with an average age between 23 and 30 years and average of 3 previous abortions. |
| Types of interventions | Group 1: prescribed 500 mg (tablets) of folic acid (Mepaco-Medifood, Egypt) daily together with 0.4mg/kg sodium tinzaparin (Innohep 4500 IU; LEO Pharma A/S, Denmark) daily subcutaneous injections. Group 2 (control group: folic acid prescribed at the same dose only without LMWH. |
| Results measures | Primary Result: viable pregnancy continuation beyond 20 weeks of gestation. Secondary Result: Results were home-baby rate, spontaneous abortion rate, intrauterine growth restriction, preeclampsia, maternal hemorrhage, heparin-induced thrombocytopenia, injection site pain and bruising, teratogenicity. |
| Results | The use of LMWH (tinzaparin) decreased the rate of early and late miscarriage and increased the rate of live births, and LMWH treatment may increase the percentage of babies at home. |